Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis

Circulation

Volumn 89, Issue 4, 1994, Pages 1802-1809

  Nicolini, Francesca A ^a   Lee, Philmo ^a   Rios, Gaddiel ^a   Kottke Marchant, Kandice ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

hirudin; Integrelin; plasminogen activators; thrombosis

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HIRUDIN; THROMBIN INHIBITOR;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0028346254     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.89.4.1802     Document Type: Article

References (34)

1. Becker RC, Gore JM. Adjuvant antiplatelet strategies in coronary thrombolysis. Circulation. 1991;83:1115-1117.
2. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920-928.
3. Bloom AL. The release of thrombin from fibrin by fibrinolysis. Br J Haematol. 1962;82:129-133.
4. Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood. 1989;74:1025-1030.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
6. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Randomised comparison of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
7. Hisia J, Hamilton WP, Kleiman N, Roberts R, Chartman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437.
8. de Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M, for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J. 1992;67:122-128.
9. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990; 322:33-42.
10. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973; 248:6490-6505.
11. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost. 1989;15:269-282.
12. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet GPIIb/IIIa receptors prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81:1284-1291.
13. Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation. 1990;82: 169-177.
14. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
15. Nicolini FA, Mehta JL, Nichols WW, Saldeen TGP, Grant M. Prostacyclin analog iloprost decreases the thrombolytic potential of t-PA in canine coronary thrombosis. Circulation. 1990;81: 1115-1122.
16. Nicolini FA, Nichols WW, Saldeen TGP, Mehta JL. Pathologic basis of failure of concurrent glyceryl trinitrate therapy to improve the efficacy of tissue-type plasminogen activator in coronary thrombosis. Cardiovasc Res. 1991;25:283-289.
17. Nicolini FA, Nichols WW, Mehta JL, Schofield R, Ross M, Player D, Phol G, Mattsson C. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-type plasminogen activator. J Am Coll Cardiol. 1992;20:228-235.
18. Nicolini FA, Nichols WW, Saldeen TGP, Khan S, Mehta JL. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. Am Heart J. 1992;124:280-288.
19. Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 1986;7:1255-1262.
20. von Clauss A. Gerinnungsphysiologogische schnellmethode zur bestimmung des fibrinogenes. Acta Haematol. 1957;17:273-246.
21. Haaland AK, Skjønsberg OH, Gravem K, Ruyter R, Godal HC. Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation. Thromb Res. 1991;61:253-259.
22. Loscalzo J. Platelet and thrombolysis. J Vasc Med Biol. 1989;1: 213-218.
23. Rote WE, Mu DX, Bates ER, Walsh DG, Nedelman MA, Lucchesi BR. Prevention of coronary rethrombosis after rt-PA: 7E3 F(ab')2 vs r-hirudin. Circulation. 1992;86(suppl I):I-410. Abstract.
24. 2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after recombinant tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation. 1989;79: 911-919.
25. Charo IF, Scarborough RM, du Mée CP, Wolf D, Phillips DR, Swift RL. Pharmacodynamics of the GPIIb-IIIa antagonist Integrelin: phase I clinical studies in normal healthy volunteers. Circulation. 1992;86(suppl I):I-260. Abstract.
26. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries, Circulation. 1992;86:1993-1999.
27. Nichols WW, Nicolini FA, Khan S, Saldeen TGP, Mehta JL. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen activator-induced thrombolysis. Am Heart J. 1993;126:285-292.
28. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
29. Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadvary P. Effects of heparin, aspirin, and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther. 1993;264: 501-508.
30. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang J, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb-IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990;16: 714-722.
31. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing reocclusion. Circulation. 1991;83:1048-1056.
32. Song A, Scarborough RM, Phillips DR, Adelman B, Strony J. Integrelin enhances fibrinolysis and prevents acute arterial reocclusion following thrombolysis in a canine anodal current model with high-grade stenosis. Circulation. 1992;86(suppl I):I-410. Abstract.
33. Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with recombinant tissue-type plasminogen activator by treatment with heparin. Circulation. 1986;74: 583-587.
34. Mehta JL, Nichols WW, Saldeen TGP. Effects of peptide 6A on coronary blood flow dynamics in canine coronary thrombosis. J Cardiovasc Pharmacol. 1989;13:803-811.